Incorrect Data and Omitted Explanation for a Calculation

In the Original Investigation entitled “Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs”¹ published in the August 6, 2019, issue of JAMA, some data were reported incorrectly. Table 4 should have indicated that assistance for generic drugs was available for Sabril, Zytiga, Reyataz, and Lexiva; for each of these 4 drugs, in the columns under “Generic Drugs,” under the headings “Total” and “PAN Foundation,” the numeral “0” should have been “1.” In addition, the row of data for “Abilify” should have been deleted. With these corrections, in the final “Total” row of Table 4, the “Brand-Name Drugs” columns should have been “55” for the “Total” column and “23” for the “PAN Foundation” column and the “Generic Drugs” columns should have been “25” for the “Total” column and “17” for the “PAN Foundation” column. Also, a statement explaining how the expense ratio was calculated was omitted. In the Methods section, at the end of the third paragraph, the final sentences should have been: “The expense ratio was calculated as patient assistance expense divided by total revenue as per the line items reported on form 990 or annual reports posted on each charity’s website. The calculation only included 1 calendar year. Other data and information from form 990 or financial statements were not included.” This article was corrected online.